 Medicare Part D
"Medicare Part D" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stand-alone drug plan offered by insurers and other private companies to beneficiaries that receive their Medicare Part A and/or B benefits through the Original Medicare Plan. It includes Medicare Private Fee-for-Service Plans that do not offer prescription drug coverage and Medicare Cost Plans offering Medicare prescription drug coverage. The plan was enacted as the Medicare Prescription Drug, Improvement and Modernization Act of 2003 with coverage beginning January 1, 2006.
| Descriptor ID |
D054524
|
| MeSH Number(s) |
N03.219.521.576.343.575.500 N03.219.521.576.343.840.938 N03.706.615.752
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Medicare Part D".
Below are MeSH descriptors whose meaning is more specific than "Medicare Part D".
This graph shows the total number of publications written about "Medicare Part D" by people in this website by year, and whether "Medicare Part D" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 | | 2010 | 2 | 0 | 2 | | 2011 | 1 | 0 | 1 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2021 | 2 | 1 | 3 | | 2022 | 3 | 0 | 3 | | 2023 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Medicare Part D" by people in Profiles.
-
Anderson KE, Xuan A, Anderson GF, Socal MP. Estimating Changes in Medicare Part D and Commercial Insurer Insulin Spending Amid Planned State-Led Biosimilar Insulin Production in California. JAMA Intern Med. 2023 07 01; 183(7):734-735.
-
Figueroa JF, Dai D, Feyman Y, Garrido MM, Tsai TC, Orav EJ, Frakt AB. Use of High-Risk Medications Among Older Adults Enrolled in Medicare Advantage Plans vs Traditional Medicare. JAMA Netw Open. 2023 06 01; 6(6):e2320583.
-
DiStefano MJ, Kang SY, Parasrampuria S, Anderson GF. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance. JAMA Health Forum. 2023 05 05; 4(5):e231090.
-
Nguyen AM, Anderson KE, Anderson G, Johnson TV. Association Between Open Payments-Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US. JAMA Ophthalmol. 2022 09 01; 140(9):855-862.
-
Anderson KE, Alexander GC, Ma C, Dy SM, Sen AP. Medicare Advantage coverage restrictions for the costliest physician-administered drugs. Am J Manag Care. 2022 07 01; 28(7):e255-e262.
-
Hussaini SMQ, Gupta A, Anderson KE, Ballreich JM, Nicholas LH, Alexander GC. Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. JAMA Netw Open. 2022 03 01; 5(3):e221117.
-
Goel V, Moran B, Kaizer AM, Sivanesan E, Patwardhan AM, Ibrahim M, DeWeerth JC, Shannon C, Shankar H. Opioid Prescriptions by Pain Medicine Physicians in the Medicare Part D Program: A Cross-Sectional Study. Anesth Analg. 2021 06 01; 132(6):1748-1755.
-
de Havenon A, Delic A, Dehoney S, Whetman P, Sheibani N, Callaghan B, Ney J, Esper GJ, Magliocco B, Nair KV. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D. Neurology. 2021 04 20; 96(16):e2132-e2137.
-
DiStefano MJ, Kang SY, Yehia F, Morales C, Anderson GF. Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs. Value Health. 2021 03; 24(3):397-403.
-
Abraham R, Wilkinson E, Jabbarpour Y, Petterson S, Bazemore A. Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients. J Am Board Fam Med. 2020 Jan-Feb; 33(1):9-16.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|